The 340B Drug Pricing Program, created in 1992, allows qualified nonprofit hospitals, health centers, and HIV clinics serving low-income patients to stretch limited resources by purchasing medications at discounted prices from pharmaceutical companies. Recent attacks on the program claim hospitals are exploiting it, but according to program defenders, the program is doing exactly what Congress designed it to do: help safety-net providers care for vulnerable patients as drug prices and pharmaceutical company profits soar.
The program’s growth reflects explicit federal policy choices, including the Affordable Care Act’s expansion of eligibility and regulatory decisions that allow patients to access medications closer to home. Rising drug prices and newer, extraordinarily expensive, life-preserving therapies have made the program more important, according to its advocates.
Pharmaceutical Company Actions
What has changed is not hospital behavior, but the aggressiveness of pharmaceutical companies seeking to limit the discounts they are legally required to provide. For-profit drug manufacturers now refuse to provide some drugs at the 340B discounted price, including improved cancer treatments, drugs for HIV, and mental health medications. New demands for extensive data submissions are bogging down hospitals, while drug companies withhold medications from contracted pharmacies that carry specialty drugs in local communities.
Hospital Reinvestment and Community Benefits
Every 340B eligible hospital is a public or nonprofit institution that cares for a high proportion of low-income people. 340B hospitals reinvest in patient care, sustaining vital services such as rural obstetrics that may otherwise close, or offer community services like free dental clinics. The program also allows hospitals to provide free and reduced-cost care for low-income and uninsured patients.
In 2024, Washington’s 340B hospitals provided more than $2.1 billion in free and reduced health care services through charity care and Medicaid underpayments, well above the value of their 340B discounts. More than 20 states have already acted to preserve access to discounted drugs, stepping in to protect the federal framework that Congress created as manufacturers impose unilateral restrictions that threaten patient access.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.heraldnet.com/opinion/comment-hosptials-staying-true-to-congress-drug-discounts/